Physical characterization and in vitro biological impact of highly aggregated antibodies separated into size-enriched populations by fluorescence-activated cell sorting

Journal of Pharmaceutical Sciences

Volumn 104, Issue 5, 2015, Pages 1575-1591

  Telikepalli, Srivalli ^a   Shinogle, Heather E ^a   Thapa, Prem S ^a   Kim, Jae Hyun ^a   Deshpande, Meghana ^b   Jawa, Vibha ^b   Middaugh, C Russell ^a   Narhi, Linda O ^b   Joubert, Marisa K ^b   Volkin, David B ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b AMGEN INC   (United States)

Author keywords

IgG; Immune response; Immunogenicity; in vitro; Monoclonal antibody; Particles; PBMC; Protein aggregation; Proteins

Indexed keywords

CARBON; CHLORINE; FLUORINE; GAMMA INTERFERON; IMMUNOGLOBULIN G2; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; LYMPHOTOXIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; NITROGEN; OXYGEN; PHYTOHEMAGGLUTININ; TUMOR NECROSIS FACTOR ALPHA; IMMUNOGLOBULIN G; MICROSPHERE; NANOPARTICLE;

ARTICLE; BIOCHEMICAL COMPOSITION; CELL STRUCTURE; CENTRIFUGATION; CHEMICAL COMPOSITION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE RELEASE; CYTOKINE RESPONSE; FLUORESCENCE ACTIVATED CELL SORTING; FLUORESCENCE SPECTROSCOPY; FREEZE THAWING; HUMAN; HUMAN CELL; HYDROPHOBICITY; IMMUNE RESPONSE; IMMUNE STATUS; IN VITRO STUDY; MICROMORPHOLOGY; MORPHOLOGY; PARTICLE SIZE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN SECONDARY STRUCTURE; ROENTGEN SPECTROSCOPY; SCANNING ELECTRON MICROSCOPY; SEDIMENTATION; SURFACE PROPERTY; TRANSMISSION ELECTRON MICROSCOPY; CHEMISTRY; CYTOLOGY; FLOW CYTOMETRY; MONONUCLEAR CELL; PROCEDURES;

ANTIBODIES, MONOCLONAL; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN G; LEUKOCYTES, MONONUCLEAR; MICROSPHERES; NANOPARTICLES; PARTICLE SIZE;

EID: 84926661231     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24379     Document Type: Article

References (65)

1. Baker MP, Reynolds HM, Lumicisi B, Bryson CJ. 2010. Immunogenicity of protein therapeutics: The key causes, consequences and challenges. Self Nonself 1(4):314-322.
2. Boven K, Knight J, Bader F, Rossert J, Eckardt KU, Casadevall N. 2005. Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: Solving the mystery. Nephrol Dial Transplant 20 Suppl 3:iii33-iii40.
3. Casadevall N. 2005. What is antibody-mediated pure red cell aplasia (PRCA)? Nephrol Dial Transplant 20 Suppl 4:iv3-iv8.
4. Chirino AJ, Ary ML, Marshall SA. 2004. Minimizing the immunogenicity of protein therapeutics. Drug Discov Today 9(2):82-90.
5. Claman HN. 1963. Tolerance to a protein antigen in adult mice and the effect of nonspecific factors. J Immunol 91:833-839.
6. Gamble CN. 1966. The role of soluble aggregates in the primary immune response of mice to human gamma globulin. Int Arch Allergy Appl Immunol 30(5):446-455.
7. Goudemand J, Rothschild C, Demiguel V, Vinciguerrat C, Lambert T, Chambost H, Borel-Derlon A, Claeyssens S, Laurian Y, Calvez T, FVIII-LFB, Recombinant FVIII study groups. 2006. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 107(1):46-51.
8. Moore WV, Leppert P. 1980. Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J Clin Endocrinol Metab 51(4):691-697.
9. Wang W, Roberts CJ, Eds. 2010. Aggregation of therapeutic proteins. Hoboken, New Jersey: John Wiley & Sons, pp 486.
10. Wang W, Singh SK, Li N, Toler MR, King KR, Nema S. 2012. Immunogenicity of protein aggregates - Concerns and realities. Int J Pharm 431(1-2):1-11.
11. Mahler HC, Friess W, Grauschopf U, Kiese S. 2009. Protein aggregation: Pathways, induction factors and analysis. J Pharm Sci 98(9):2909-2934.
12. Cromwell ME, Hilario E, Jacobson F. 2006. Protein aggregation and bioprocessing. AAPS J 8(3):E572-E579.
13. Joubert MK, Luo Q, Nashed-Samuel Y, Wypych J, Narhi LO. 2011. Classification and characterization of therapeutic antibody aggregates. J Biol Chem 286(28):25118-25133.
14. Luo Q, Joubert MK, Stevenson R, Ketchem RR, Narhi LO, Wypych J. 2011. Chemical modifications in therapeutic protein aggregates generated under different stress conditions. J Biol Chem 286(28):25134-25144.
15. Telikepalli SN, Kumru OS, Kalonia C, Esfandiary R, Joshi SB, Middaugh CR, Volkin DB. 2014. Structural characterization of IgG1 mAb aggregates and particles generated under various stress conditions. J Pharm Sci 103(3):796-809.
16. Iwura T, Fukuda J, Yamazaki K, Arisaka F. 2014. Conformational stability, reversibility and heat-induced aggregation of alpha-1-acid glycoprotein. J Biochem 156(6):345-352.
17. Liu L, Braun LJ, Wang W, Randolph TW, Carpenter JF. 2014. Freezing-induced perturbation of tertiary structure of a monoclonal antibody. J Pharm Sci 103(7):1979-1986.
18. Sahin E, Grillo AO, Perkins MD, Roberts CJ. 2010. Comparative effects of pH and ionic strength on protein-protein interactions, unfolding, and aggregation for IgG1 antibodies. J Pharm Sci 99(12):4830-4848.
19. Sharma B. 2007. Immunogenicity of therapeutic proteins. Part 2: Impact of container closures. Biotechnol Adv 25(3):318-324.
20. Shire SJ, Shahrokh Z, Liu J. 2004. Challenges in the development of high protein concentration formulations. J Pharm Sci 93(6):1390-1402.
21. Wang W. 2005. Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm 289(1-2):1-30.
22. Wiesbauer J, Prassl R, Nidetzky B. 2013. Renewal of the air-water interface as a critical system parameter of protein stability: Aggregation of the human growth hormone and its prevention by surface-active compounds. Langmuir 29(49):15240-15250.
23. Schellekens H. 2005. Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant 20 Suppl 6:vi3-vi9.
24. Ponce R, Abad L, Amaravadi L, Gelzleichter T, Gore E, Green J, Gupta S, Herzyk D, Hurst C, Ivens IA, Kawabata T, Maier C, Mounho B, Rup B, Shankar G, Smith H, Thomas P, Wierda D. 2009. Immunogenicity of biologically-derived therapeutics: Assessment and interpretation of nonclinical safety studies. Regul Toxicol Pharmacol 54(2):164-182.
25. Schellekens H. 2002. Immunogenicity of therapeutic proteins: Clinical implications and future prospects. Clin Ther 24(11):1720-1740; discussion 1719.
26. Jahn EM, Schneider CK. 2009. How to systematically evaluate immunogenicity of therapeutic proteins - Regulatory considerations. N Biotechnol 25(5):280-286.
27. Johnson R, Jiskoot W. 2012. Models for evaluation of relative immunogenic potential of protein particles in biopharmaceutical protein formulations. J Pharm Sci 101(10):3586-3592.
28. Perry LC, Jones TD, Baker MP. 2008. New approaches to prediction of immune responses to therapeutic proteins during preclinical development. Drugs R&D 9(6):385-396.
29. Koren E, De Groot AS, Jawa V, Beck KD, Boone T, Rivera D, Li L, Mytych D, Koscec M, Weeraratne D, Swanson S, Martin W. 2007. Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein. Clin Immunol 124(1):26-32.
30. Tatarewicz SM, Wei X, Gupta S, Masterman D, Swanson SJ, Moxness MS. 2007. Development of a maturing T-cell-mediated immune response in patients with idiopathic Parkinson's disease receiving r-metHuGDNF via continuous intraputaminal infusion. J Clin Immunol 27(6):620-627.
31. Wullner D, Zhou L, Bramhall E, Kuck A, Goletz TJ, Swanson S, Chirmule N, Jawa V. 2010. Considerations for optimization and validation of an in vitro PBMC derived T cell assay for immunogenicity prediction of biotherapeutics. Clin Immunol 137(1):5-14.
32. Jaber A, Baker M. 2007. Assessment of the immunogenicity of different interferon beta-1a formulations using ex vivo T-cell assays. J Pharm Biomed Anal 43(4):1256-1261.
33. Stickler M, Rochanayon N, Razo OJ, Mucha J, Gebel W, Faravashi N, Chin R, Holmes S, Harding FA. 2004. An in vitro human cell-based assay to rank the relative immunogenicity of proteins. Toxicol Sci 77(2):280-289.
34. Brinks V, Jiskoot W, Schellekens H. 2011. Immunogenicity of therapeutic proteins: The use of animal models. Pharm Res 28(10):2379-2385.
35. Hermeling S, Aranha L, Damen JM, Slijper M, Schellekens H, Crommelin DJ, Jiskoot W. 2005. Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b. Pharm Res 22(12):1997-2006.
36. Braun A, Kwee L, Labow MA, Alsenz J. 1997. Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice. Pharm Res 14(10):1472-1478.
37. Stewart TA, Hollingshead PG, Pitts SL, Chang R, Martin LE, Oakley H. 1989. Transgenic mice as a model to test the immunogenicity of proteins altered by site-specific mutagenesis. Mol Biol Med 6(4):275-281.
38. Whiteley PJ, Lake JP, Selden RF, Kapp JA. 1989. Tolerance induced by physiological levels of secreted proteins in transgenic mice expressing human insulin. J Clin Invest 84(5):1550-1554.
39. Gaitonde P, Balu-Iyer SV. 2011. In vitro immunogenicity risk assessment of therapeutic proteins in preclinical setting. Drug Des Disco Methods Mol Biol 716:267-280.
40. Joubert MK, Hokom M, Eakin C, Zhou L, Deshpande M, Baker MP, Goletz TJ, Kerwin BA, Chirmule N, Narhi LO, Jawa V. 2012. Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses. J Biol Chem 287(30):25266-25279.
41. Narhi LO, Schmit J, Bechtold-Peters K, Sharma D. 2012. Classification of protein aggregates. J Pharm Sci 101(2):493-498.
42. Rombach-Riegraf V, Allard C, Angevaare E, Matter A, Ossuli B, Strehl R, Raulf F, Bluemel M, Egodage K, Jeschke M, Koulov AV. 2013. Size fractionation of microscopic protein aggregates using a preparative fluorescence-activated cell sorter. J Pharm Sci 102(7):2128-2135.
43. Espargaro A, Sabate R, Ventura S. 2012. Thioflavin-S staining coupled to flow cytometry. A screening tool to detect in vivo protein aggregation. Mol BioSystems 8(11):2839-2844.
44. Mach H, Bhambhani A, Meyer BK, Burek S, Davis H, Blue JT, Evans RK. 2011. The use of flow cytometry for the detection of subvisible particles in therapeutic protein formulations. J Pharm Sci 100(5):1671-1678.
45. Nishi H, Mathas R, Furst R, Winter G. 2014. Label-free flow cytometry analysis of subvisible aggregates in liquid IgG1 antibody formulations. J Pharm Sci 103(1):90-99.
46. Ludwig DB, Trotter JT, Gabrielson JP, Carpenter JF, Randolph TW. 2011. Flow cytometry: A promising technique for the study of silicone oil-induced particulate formation in protein formulations. Anal Biochem 410(2):191-199.
47. Bi V, Jawa V, Joubert MK, Kaliyaperumal A, Eakin C, Richmond K, Pan O, Sun J, Hokom M, Goletz TJ, Wypych J, Zhou L, Kerwin BA, Narhi LO, Arora T. 2013. Development of a human antibody tolerant mouse model to assess the immunogenicity risk due to aggregated biotherapeutics. J Pharm Sci 102(10):3545-3555.
48. Shukla AA, Hubbard B, Tressel T, Guhan S, Low D. 2007. Downstream processing of monoclonal antibodies - Application of platform approaches. J Chromatogr B 848(1):28-39.
49. Kalonia C, Kumru OS, Kim JH, Middaugh CR, Volkin DB. 2013. Radar chart array analysis to visualize effects of formulation variables on IgG1 particle formation as measured by multiple analytical techniques. J Pharm Sci 102(12):4256-4267.
50. Kalonia C, Kumru OS, Prajapati I, Mathaes R, Engert J, Zhou S, Middaugh CR, Volkin DB. 2015. Calculating the mass of subvisible protein particles with improved accuracy using micro-flow imaging data. J Pharm Sci 104(2):536-547.
51. Mach H, Middaugh CR. 2010. Ultraviolet spectroscopy as a tool in therapeutic protein development. J Pharm Sci 100(4):1214-1227.
52. Kumru OS, Liu J, Ji JA, Cheng W, Wang YJ, Wang T, Joshi SB, Middaugh CR, Volkin DB. 2012. Compatibility, physical stability, and characterization of an IgG4 monoclonal antibody after dilution into different intravenous administration bags. J Pharm Sci 101(10):3636-3650.
53. Jiao N. 2014. Personal communication.
54. Shapiro HM. 2003. Practical flow cytometry. New Jersey: Wiley, pp 681.
55. Kim JH, Iyer V, Joshi SB, Volkin DB, Middaugh CR. 2012. Improved data visualization techniques for analyzing macromolecule structural changes. Protein Sci 21(10):1540-1553.
56. Hermeling S, Schellekens H, Maas C, Gebbink MF, Crommelin DJ, Jiskoot W. 2006. Antibody response to aggregated human interferon alpha2b in wild-type and transgenic immune tolerant mice depends on type and level of aggregation. J Pharm Sci 95(5):1084-1096.
57. Johansen P, Senti G, Martinez Gomez JM, Wuthrich B, Bot A, Kundig TM. 2005. Heat denaturation, a simple method to improve the immunotherapeutic potential of allergens. Eur J Immunol 35(12):3591-3598.
58. Fradkin AH, Carpenter JF, Randolph TW. 2009. Immunogenicity of aggregates of recombinant human growth hormone in mouse models. J Pharm Sci 98(9):3247-3264.
59. Filipe V, Jiskoot W, Basmeleh AH, Halim A, Schellekens H, Brinks V. 2012. Immunogenicity of different stressed IgG monoclonal antibody formulations in immune tolerant transgenic mice. mAbs 4(6):740-752.
60. Fradkin AH, Mozziconacci O, Schoneich C, Carpenter JF, Randolph TW. 2014. UV photodegradation of murine growth hormone: Chemical analysis and immunogenicity consequences. Eur J Pharm Biopharm 87(2):395-402.
61. Rombach-Riegraf V, Karle AC, Wolf B, Sorde L, Koepke S, Gottlieb S, Krieg J, Djidja MC, Baban A, Spindeldreher S, Koulov AV, Kiessling A. 2014. Aggregation of human recombinant monoclonal antibodies influences the capacity of dendritic cells to stimulate adaptive T-cell responses in vitro. Public Libr Sci One 9(1):e86322.
62. van Beers MM, Gilli F, Schellekens H, Randolph TW, Jiskoot W. 2012. Immunogenicity of recombinant human interferon beta interacting with particles of glass, metal, and polystyrene. J Pharm Sci 101(1):187-199.
63. van Beers MM, Sauerborn M, Gilli F, Brinks V, Schellekens H, Jiskoot W. 2011. Oxidized and aggregated recombinant human interferon beta is immunogenic in human interferon beta transgenic mice. Pharm Res 28(10):2393-2402.
64. Fradkin AH, Carpenter JF, Randolph TW. 2011. Glass particles as an adjuvant: A model for adverse immunogenicity of therapeutic proteins. J Pharm Sci 100(11):4953-4964.
65. Seong SY, Matzinger P. 2004. Hydrophobicity: An ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol 4(6):469-478.